Progestins and progesterone in hormone replacement therapy and the risk of breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 96, Issue 2, 2005, Pages 95-108

  Campagnoli, Carlo ^a   Clavel Chapelon, Françoise ^b   Kaaks, Rudolf ^c   Peris, Clementina ^a   Berrino, Franco ^d  

^a Sant'Anna Hospital   (Italy)

^b INSERM   (France)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Estrogen; Hormone replacement therapy; Insulin; Insulin like growth factor I; Progesterone; Progestins; Sex hormone binding globulin

Indexed keywords

CELL ENZYME; CHLORMADINONE ACETATE; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DEMEGESTONE; DYDROGESTERONE; ESTRADIOL; ESTROGEN; GESTAGEN; HYDROXYPROGESTERONE; LEVONORGESTREL; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NANDROLONE; NANDROLONE DERIVATIVE; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; PROGESTERONE; PROGESTERONE DERIVATIVE; PROMEGESTONE; RETROPROGESTERONE; SOMATOMEDIN C; TRIMEGESTONE; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER RISK; CLIMACTERIUM; CLINICAL TRIAL; DENSITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; EPIDEMIOLOGICAL DATA; ESTROGEN ACTIVITY; HORMONE SUBSTITUTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; NONHUMAN; POSTMENOPAUSE; PRESCRIPTION; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTERONE; PROGESTINS; RISK FACTORS;

EID: 23244452258     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.02.014     Document Type: Review

References (139)

1. J. Clemmesen Statistical studies in the aetiology of malignant neoplasms, 3 Acta Pathol. Microbiol. Scand. 209 S1 1969 S1 S58
2. D. Trichopoulos, B. MacMahon, and P. Cole Menopause and breast cancer risk J. Natl. Cancer Inst. 48 3 1972 605 613
3. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 9114 1998 1451 1467
4. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies J. Natl. Cancer Inst. 94 8 2002 606 616
5. R.C. Travis, and T.J. Key Oestrogen exposure and breast cancer risk Breast Cancer Res. 5 5 2003 239 247
6. A. Micheli, P. Muti, G. Secreto, V. Krogh, E. Meneghini, E. Venturelli, S. Sieri, V. Pala, and F. Berrino Endogenous sex hormones and subsequent breast cancer in pre-menopausal women Int. J. Cancer 112 2 2004 312 318
7. G. Secreto, and B. Zumoff Abnormal production of androgens in women with breast cancer Anticancer Res. 14 5B 1994 2113 2117
8. T.J. Key, and M.C. Pike The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer Eur. J. Cancer Clin. Oncol. 24 1 1988 29 43
9. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, D. Bonds, R. Brunner, R. Brzyski, B. Caan, R. Chlebowski, D. Curb, M. Gass, J. Hays, G. Heiss, S. Hendrix, B.V. Howard, J. Hsia, A. Hubbell, R. Jackson, K.C. Johnson, H. Judd, J.M. Kotchen, L. Kuller, A.Z. LaCroix, D. Lane, R.D. Langer, N. Lasser, C.E. Lewis, J. Manson, K. Margolis, J. Ockene, M.J. O'Sullivan, L. Phillips, R.L. Prentice, C. Ritenbaugh, J. Robbins, J.E. Rossouw, G. Sarto, M.L. Stefanick, L. Van Horn, J. Wactawski-Wende, R. Wallace, and S. Wassertheil-Smoller Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 14 2004 1701 1712
10. C.M. Viscoli, L.M. Brass, W.N. Kernan, P.M. Sarrel, S. Suissa, and R.I. Horwitz A clinical trial of estrogen-replacement therapy after ischemic stroke N. Engl. J. Med. 345 17 2001 1243 1249
11. R.K. Ross, A. Paganini-Hill, P.C. Wan, and M.C. Pike Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin J. Natl. Cancer Inst. 92 4 2000 328 332
12. P.G. Moorman, H. Kuwabara, R.C. Millikan, and B. Newman Menopausal hormones and breast cancer in a biracial population Am. J. Public Health 90 6 2000 966 971
13. C.L. Chen, N.S. Weiss, P. Newcomb, W. Barlow, and E. White Hormone replacement therapy in relation to breast cancer JAMA 287 6 2002 734 741
14. J.V. Porch, I.M. Lee, N.R. Cook, K.M. Rexrode, and J.E. Burin Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States) Cancer Causes Contr. 13 9 2002 847 854
15. L.K. Weiss, R.T. Burkman, K.L. Cushing-Haugen, L.F. Voigt, M.S. Simon, J.R. Daling, S.A. Norman, L. Bernstein, G. Ursin, P.A. Marchbanks, B.L. Strom, J.A. Berlin, A.L. Weber, D.R. Doody, P.A. Wingo, J.A. McDonald, K.E. Malone, S.G. Folger, and R. Spirtas Hormone replacement therapy regimens and breast cancer risk (1) Obstet. Gynecol. 100 6 2002 1148 1158
16. C.I. Li, K.E. Malone, P.L. Porter, N.S. Weiss, M.T. Tang, K.L. Cushing-Haugen, and J.R. Daling Relationship between long durations and different regimens of hormone therapy and risk of breast cancer JAMA 289 24 2003 3254 3263
17. H.L. Olsson, C. Ingvar, and A. Bladstrom Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden Cancer 97 6 2003 1387 1392
18. V. Beral Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 9382 2003 419 427
19. P.A. Newcomb, L. Titus-Ernstoff, K.M. Egan, A. Trentham-Dietz, J.A. Baron, B.E. Storer, W.C. Willett, and M.J. Stampfer Postmenopausal estrogen and progestin use in relation to breast cancer risk Cancer Epidemiol. Biomarkers Prev. 11 7 2002 593 600
20. C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 283 4 2000 485 491
21. R.T. Chlebowski, S.L. Hendrix, R.D. Langer, M.L. Stefanick, M. Gass, D. Lane, R.J. Rodabough, M.A. Gilligan, M.G. Cyr, C.A. Thomson, J. Khandekar, H. Petrovitch, and A. McTiernan Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial JAMA 289 24 2003 3243 3253
22. S. Hulley, C. Furberg, E. Barrett-Connor, J. Cauley, D. Grady, W. Haskell, R. Knopp, M. Lowery, S. Satterfield, H. Schrott, E. Vittinghoff, and D. Hunninghake Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) JAMA 288 1 2002 58 66
23. M.C. Pike, and R.K. Ross Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer Steroids 65 10-11 2000 659 664
24. R.J. Santen, J. Pinkerton, C. McCartney, and G.R. Petroni Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy J. Clin. Endocrinol. Metab. 86 1 2001 16 23
25. C. Stahlberg, A.T. Pederson, E. Lynge, and B. Ottesen Hormone replacement therapy and risk of breast cancer: the role of progestins Acta Obstet. Gynecol. Scand. 82 7 2003 335 344
26. A. Fournier, F. Berrino, E. Riboli, V. Avenel, F. Clavel-Chapelon, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int. J. Cancer 114 (2005) 448-454.
27. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society Menopause 10 2 2003 113 132
28. D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster, and D. Petitti Hormone replacement therapy and endometrial cancer risk: a meta-analysis Obstet. Gynecol. 85 2 1995 304 313
29. K.L. Cushing, N.S. Weiss, L.F. Voigt, B. McKnight, and S.A. Beresford Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens Obstet. Gynecol. 91 1 1998 35 39
30. The Writing Group for the, PEPI, Trial Effects of hormone replacement therapy on endometrial histology in postmenopausal, women. The Postmenopausal Estrogen/Progestin Interventions (PEPI), Trial JAMA 275 5 1996 370 375
31. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, and J. Ockene Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 3 2002 321 333
32. C. Campagnoli, L. Lesca, C. Cantamessa, and C. Peris Long-term hormone replacement treatment in menopause: new choices, old apprehensions: recent findings Maturitas 18 1 1993 21 46
33. L.A. Mattsson, G. Cullberg, and G. Samsioe Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints Maturitas 4 2 1982 95 102
34. U. Omodei, and L. Speroff Outlook on continuous oestrogen-progestin therapy Contemp. Obstet. Gynecol. 31 1988 S171 S173
35. M. Doren, G. Reuther, H.W. Minne, and H.P. Schneider Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women Am. J. Obstet. Gynecol. 173 5 1995 1446 1451
36. R.G. Hahn Compliance considerations with estrogen replacement: withdrawal bleeding and other factors Am. J. Obstet. Gynecol. 161 6 1989 1854 1858
37. H. Jernstrom, P.O. Bendahl, J. Lidfeldt, C. Nerbrand, C.D. Agardh, and G. Samsioe A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden) Cancer Causes Contr. 14 7 2003 673 680
38. C. Magnusson, J.A. Baron, N. Correia, R. Bergstrom, H.O. Adami, and I. Persson Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy Int. J. Cancer 81 3 1999 339 344
39. C. Stahlberg, A.T. Pedersen, E. Lynge, Z.J. Andersen, N. Keiding, Y.A. Hundrup, E.B. Obel, and B. Ottesen Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe Int. J. Cancer 109 5 2004 721 727
40. D.L. Moyer, B. de Lignieres, P. Driguez, and J.P. Pez Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes Fertil. Steril. 59 5 1993 992 997
41. J.Y. Gillet, G. Andre, B. Faguer, R. Erny, M. Buvat-Herbaut, M.A. Domin, J.M. Kuhn, B. Hedon, E. Drapier-Faure, and J. Barrat Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study Maturitas 19 2 1994 103 115
42. T.J. Key, P.N. Appleby, G.K. Reeves, A. Roddam, J.F. Dorgan, C. Longcope, F.Z. Stanczyk, H.E. Stephenson Jr., R.T. Falk, R. Miller, A. Schatzkin, D.S. Allen, I.S. Fentiman, T.J. Key, D.Y. Wang, M. Dowsett, H.V. Thomas, S.E. Hankinson, P. Toniolo, A. Akhmedkhanov, K. Koenig, R.E. Shore, A. Zeleniuch-Jacquotte, Berrino, P. Muti, A. Micheli, V. Krogh, S. Sieri, V. Pala, E. Venturelli, G. Secreto, E. Barrett-Connor, G.A. Laughlin, M. Kabuto, S. Akiba, R.G. Stevens, K. Neriishi, C.E. Land, J.A. Cauley, L.H. Kuller, S.R. Cummings, K.J. Helzlsouer, A.J. Alberg, T.L. Bush, G.W. Comstock, G.B. Gordon, S.R. Miller, and C. Longcope Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women J. Natl. Cancer Inst. 95 2003 1218 1226
43. K. Kerlikowske, D.L. Miglioretti, R. Ballard-Barbash, D.L. Weaver, D.S. Buist, W.E. Barlow, G. Cutter, B.M. Geller, B. Yankaskas, S.H. Taplin, and P.A. Carney Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population J. Clin. Oncol. 21 23 2003 4314 4321
44. W.C. Willett, G. Colditz, and M. Stampfer Postmenopausal estrogens-opposed, unopposed, or none of the above JAMA 283 4 2000 534 535
45. B. de Lignières, F. de Vathaire, S. Fournier, R. Urbinelli, F. Allaert, M.G. Le, and F. Kuttenn Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women Climacteric 5 4 2002 332 340
46. J.A. Simon, D.E. Robinson, M.C. Andrews, J.R. Hildebrand III, M.L. Rocci Jr., R.E. Blake, and G.D. Hodgen The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone Fertil. Steril. 60 1 1993 26 33
47. M.I. Whitehead, and D. Fraser The effects of estrogens and progestogens on the endometrium. Modern approach to treatment Obstet. Gynecol. Clin. North Am. 14 1 1987 299 320
48. S.A. Pasquale, G.A. Bachmann, R.G. Foldesy, R.E. Blackwell, and J.P. Levine Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women Fertil. Steril. 68 5 1997 810 815
49. J. Russo, M.H. Lareef, Q. Tahin, Y.F. Hu, C. Slater, X. Ao, and I.H. Russo 17Beta-estradiol is carcinogenic in human breast epithelial cells J. Steroid Biochem. Mol. Biol. 80 2 2002 149 162
50. J. Russo, and I.H. Russo Genotoxicity of steroidal estrogens Trends Endocrinol. Metab. 15 5 2004 211 214
51. S.D. Groshong, G.I. Owen, B. Grimison, I.E. Schauer, M.C. Todd, T.A. Langan, R.A. Sclafani, C.A. Lange, and K.B. Horwitz Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27 (Kip1) Mol. Endocrinol. 11 11 1997 1593 1607
52. C.A. Lange, J.K. Richer, and K.B. Horwitz Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals Mol. Endocrinol. 13 6 1999 829 836
53. E.A. Musgrove, C.S. Lee, and R.L. Sutherland Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes Mol. Cell. Biol. 11 10 1991 5032 5043
54. R.L. Sutherland, C.S. Lee, R.S. Feldman, and E.A. Musgrove Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists J. Steroid Biochem. Mol. Biol. 41 3-8 1992 315 321
55. R.L. Sutherland, O.W. Prall, C.K. Watts, and E.A. Musgrove Estrogen and progestin regulation of cell cycle progression J. Mammary Gland. Biol. Neoplasia 3 1 1998 63 72
56. B. de Lignières Effects of progestogens on the postmenopausal breast Climacteric 5 3 2002 229 235
57. J. Eden Progestins and breast cancer Am. J. Obstet. Gynecol. 188 5 2003 1123 1131
58. J.R. Pasqualini, J. Paris, R. Sitruk-Ware, G. Chetrite, and J. Botella Progestins and breast cancer J. Steroid Biochem. Mol. Biol. 65 1-6 1998 225 235
59. D.J. Ferguson, and T.J. Anderson Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast Br. J. Cancer 44 2 1981 177 181
60. T.A. Longacre, and S.A. Bartow A correlative morphologic study of human breast and endometrium in the menstrual cycle Am. J. Surg. Pathol. 10 6 1986 382 393
61. L. Dahmoush, M.C. Pike, and M.F. Press Hormones and breast cell proliferation R.A. Lobo Treatment of the postmenopausal women: basic and clinic aspects 1994 Raven Press New York 325 337
62. L.J. Hofseth, A.M. Raafat, J.R. Osuch, D.R. Pathak, C.A. Slomski, and S.Z. Haslam Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast J. Clin. Endocrinol. Metab. 84 12 1999 4559 4565
63. C. Johansson, T.J. Anderson, R. Bergstrom, A. Lindgren, and R. Persson Epithelial proliferation in the normal human breast in relation to endogenous hormones and oral contraceptive use Breast 7 1998 162 167
64. H. Olsson, H. Jernstrom, P. Alm, H. Kreipe, C. Ingvar, P.E. Jonsson, and S. Ryden Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors Breast Cancer Res. Treat. 40 2 1996 187 196
65. G. Soderqvist, E. Isaksson, B. von Schoultz, K. Carlstrom, E. Tani, and L. Skoog Proliferation of breast epithelial cells in healthy women during the menstrual cycle Am. J. Obstet. Gynecol. 176 1 1997 123 128
66. J. Russo, B.A. Gusterson, A.E. Rogers, I.H. Russo, S.R. Wellings, and M.J. van Zwieten Comparative study of human and rat mammary tumorigenesis Lab. Invest. 62 3 1990 244 278
67. R.B. Clarke Human breast cell proliferation and its relationship to steroid receptor expression Climacteric 7 2 2004 129 137
68. I.J. Laidlaw, R.B. Clarke, A. Howell, A.W. Owen, C.S. Potten, and E. Anderson The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone Endocrinology 136 1 1995 164 171
69. J.M. Foidart, C. Colin, X. Denoo, J. Desreux, A. Beliard, S. Fournier, and B. de Lignieres Estradiol and progesterone regulate the proliferation of human breast epithelial cells Fertil. Steril. 69 5 1998 963 969
70. B.E. Henderson, M.C. Pike, and J.T. Casagrande Breast cancer and the oestrogen window hypothesis Lancet 2 8242 1981 363 364
71. H. Vainio, and F. Bianchini Weight Control and Physical Activity, IARC Handbooks of Cancer Prevention vol. 6 2002 IARC Press Lyon
72. L. Bernstein, J.M. Yuan, R.K. Ross, M.C. Pike, R. Hanisch, R. Lobo, F. Stanczyk, Y.T. Gao, and B.E. Henderson Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies Cancer Causes Contr. 1 1 1990 51 58
73. D. Drafta, A.E. Schindler, S.M. Milcu, E. Keller, E. Stroe, E. Horodniceanu, and I. Balanescu Plasma hormones in pre- and postmenopausal breast cancer J. Steroid Biochem. 13 7 1980 793 802
74. W.B. Malarkey, L.L. Schroeder, V.C. Stevens, A.G. James, and R.R. Lanese Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease Cancer Res. 37 12 1977 4655 4659
75. F. Meyer, J.B. Brown, A.S. Morrison, and B. MacMahon Endogenous sex hormones, prolactin, and breast cancer in premenopausal women J. Natl. Cancer Inst. 77 3 1986 613 616
76. G. Secreto, P. Toniolo, F. Berrino, C. Recchione, S. Di Pietro, G. Fariselli, and A. Decarli Increased androgenic activity and breast cancer risk in premenopausal women Cancer Res. 44 12 1984 5902 5905
77. R. Grattarola The premenstrual endometrial pattern of women with breast cancer. A study of progestational activity Cancer 17 5 1964 1119 1122
78. L. Speroff The meaning of mammographic breast density in users of postmenopausal hormone therapy Maturitas 41 3 2002 171 175
79. G.A. Greendale, B.A. Reboussin, S. Slone, C. Wasilauskas, M.C. Pike, and G. Ursin Postmenopausal hormone therapy and change in mammographic density J. Natl. Cancer Inst. 95 1 2003 30 37
80. A.M. Oza, and N.F. Boyd Mammographic parenchymal patterns: a marker of breast cancer risk Epidemiol. Rev. 15 1 1993 196 208
81. N.F. Boyd, G.S. Dite, J. Stone, A. Gunasekara, D.R. English, M.R. McCredie, G.G. Giles, D. Tritchler, A. Chiarelli, M.J. Yaffe, and J.L. Hopper Heritability of mammographic density, a risk factor for breast cancer N. Engl. J. Med. 347 12 2002 886 894
82. C. Byrne, G.A. Colditz, W.C. Willett, F.E. Speizer, M. Pollak, and S.E. Hankinson Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density Cancer Res. 60 14 2000 3744 3748
83. N.F. Boyd, C. Greenberg, G. Lockwood, L. Little, L. Martin, J. Byng, M. Yaffe, and D. Tritchler Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group J. Natl. Cancer Inst. 89 7 1997 488 496
84. R.T. Chlebowski, and A. McTiernan Biological significance of interventions that change breast density J. Natl. Cancer Inst. 95 1 2003 4 5
85. C. Campagnoli, C. Abbà, S. Ambroggio, N. Biglia, and R. Ponzone Breast cancer and hormone replacement therapy: putting the risk into perspective Gynecol. Endocrinol. 15 S6 2001 S53 S60
86. R.D. Gambrell, R.C. Maier, and B.I. Sanders Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users Obstet. Gynecol. 62 3 1983 435 443
87. P. Conner, G. Soderqvist, L. Skoog, T. Graser, F. Walter, E. Tani, K. Carlstrom, and B. von Schoultz Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology Breast Cancer Res. Treat. 78 2 2003 159 165
88. D.F. Hargreaves, F. Knox, R. Swindell, C.S. Potten, and N.J. Bundred Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy Br. J. Cancer 78 7 1998 945 949
89. P.D. Darney The androgenicity of progestins Am. J. Med. 98 S1A 1995 S104 S110
90. A.E. Schindler, C. Campagnoli, R. Druckmann, J. Huber, J.R. Pasqualini, K.W. Schweppe, and J.H.H. Thijssen Classification and pharmacology of progestins Maturitas 46 S1 2003 S7 S16
91. J.M. Bentel, S.N. Birrell, M.A. Pickering, D.J. Holds, D.J. Horsfall, and W.D. Tilley Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells Mol. Cell. Endocrinol. 154 1-2 1999 11 20
92. R. Kaaks Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Contr. 7 6 1996 605 625
93. R.R. Kazer Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis Int. J. Cancer 62 4 1995 403 406
94. P.F. Bruning, J.M. Bonfrer, P.A. van Noord, A.A. Hart, M. Jong-Bakker, and W.J. Nooijen Insulin resistance and breast-cancer risk Int. J. Cancer 52 4 1992 511 516
95. D.A. Lawlor, G.D. Smith, and S. Ebrahim Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study Cancer Causes Contr. 15 3 2004 267 275
96. A. Malin, Q. Dai, H. Yu, X.O. Shu, F. Jin, Y.T. Gao, and W. Zheng Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma Cancer 100 4 2004 694 700
97. P. Muti, T. Quattrin, B.J. Grant, V. Krogh, A. Micheli, H.J. Schunemann, M. Ram, J.L. Freudenheim, S. Sieri, M. Trevisan, and F. Berrino Fasting glucose is a risk factor for breast cancer: a prospective study Cancer Epidemiol. Biomarkers Prev. 11 11 2002 1361 1368
98. C. Schairer, D. Hill, S.R. Sturgeon, T. Fears, M. Pollak, C. Mies, R.G. Ziegler, R.N. Hoover, and M.E. Sherman Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women Int. J. Cancer 108 5 2004 773 779
99. J.E. Nestler, and D.J. Jakubowicz Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome N. Engl. J. Med. 335 9 1996 617 623
100. L. Poretsky, and M.F. Kalin The gonadotropic function of insulin Endocr. Rev. 8 2 1987 132 141
101. F. Berrino, C. Bellati, S. Oldani, A. Mastroianni, G. Allegro, E. Berselli, E. Venturelli, A. Cavalleri, M. Cambie', V. Pala, P. Pasanisi, and G. Secreto DIANA trials on diet and endogenous hormones E. Riboli R. Lambert Nutrition and Lifestyle: Opportunities for Cancer Prevention 2002 IARC Scientific Publications no. 156 Lyon 439 444
102. R. Kaaks, C. Bellati, E. Venturelli, S. Rinaldi, G. Secreto, C. Biessy, V. Pala, S. Sieri, and F. Berrino Effect of dietary intervention on IGF-I and IGF-binding proteins and related alterations in sex steroid metabolism: the Diet and Androgens (DIANA) Randomized Trial Eur. J. Clin. Nutr. 57 9 2003 1088 1979
103. J.P. Thissen, J.M. Ketelslegers, and L.E. Underwood Nutritional regulation of the insulin-like growth factors Endocr. Rev. 15 1 1994 80 101
104. R. Kaaks, and A. Lukanova Energy balance and cancer: the role of insulin and insulin-like growth factor-I Proc. Nutr. Soc. 60 1 2001 91 106
105. I.H. Hamelers, and P.H. Steenbergh Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells Endocr. Relat. Cancer 10 2 2003 331 345
106. B.R. Westley, and F.E. May Role of insulin-like growth factors in steroid modulated proliferation J. Steroid Biochem. Mol. Biol. 51 1-2 1994 1 9
107. M.N. Pollak, E.S. Schernhammer, and S.E. Hankinson Insulin-like growth factors and neoplasia Nat. Rev. Cancer 4 7 2004 505 518
108. A.G. Renehan, M. Zwahlen, C. Minder, S.T. O'Dwyer, S.M. Shalet, and M. Egger Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis Lancet 363 9418 2004 1346 1353
109. R. Kaaks, E. Lundin, S. Rinaldi, J. Manjer, C. Biessy, S. Soderberg, P. Lenner, L. Janzon, E. Riboli, G. Berglund, and G. Hallmans Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden Cancer Causes Contr. 13 4 2002 307 316
110. E.E. Nachtigall Sex hormone binding globulin and breast cancer risk Prim. Care Update Obstet. Gynecol. 6 1999 39 43
111. F. Berrino, P. Muti, A. Micheli, G. Bolelli, V. Krogh, R. Sciajno, P. Pisani, S. Panico, and G. Secreto Serum sex hormone levels after menopause and subsequent breast cancer J. Natl. Cancer Inst. 88 5 1996 291 296
112. N. Fortunati, M. Becchis, M.G. Catalano, A. Comba, P. Ferrera, M. Raineri, L. Berta, and R. Frairia Sex hormone-binding globulin, its membrane receptor, and breast cancer: a new approach to the modulation of estradiol action in neoplastic cells J. Steroid Biochem. Mol. Biol. 69 1-6 1999 473 479
113. B. Andersson, L.A. Mattsson, L. Hahn, P. Marin, L. Lapidus, G. Holm, B.A. Bengtsson, and P. Bjorntorp Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus J. Clin. Endocrinol. Metab. 82 2 1997 638 643
114. U.J. Gaspard, J.M. Gottal, and F.A. van den Brule Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects Maturitas 21 3 1995 171 178
115. U.J. Gaspard, O.J. Wery, A.J. Scheen, C. Jaminet, and P.J. Lefebvre Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women Climacteric 2 2 1999 93 100
116. S.R. Lindheim, S.C. Presser, E.C. Ditkoff, M.A. Vijod, F.Z. Stanczyk, and R.A. Lobo A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin Fertil. Steril. 60 4 1993 664 667
117. S.R. Lindheim, D.M. Duffy, T. Kojima, M.A. Vijod, F.Z. Stanczyk, and R.A. Lobo The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women Fertil. Steril. 62 6 1994 1176 1180
118. K.L. Margolis, D.E. Bonds, R.J. Rodabough, L. Tinker, L.S. Phillips, C. Allen, T. Bassford, G. Burke, J. Torrens, and B.V. Howard Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial Diabetologia 47 7 2004 1175 1187
119. J.C. Stevenson The metabolic and cardiovascular consequences of HRT Br. J. Clin. Pract. 49 2 1995 87 90
120. C. Campagnoli, N. Biglia, C. Peris, and P. Sismondi Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause Gynecol. Endocrinol. 9 1 1995 67 74
121. C. Campagnoli, N. Biglia, P. Belforte, D. Botta, E. Pedrini, and P. Sismondi Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables Eur. J. Gynaecol. Oncol. 13 2 1992 139 154
122. C. Campagnoli, C. Abbà, S. Ambroggio, and C. Peris Differential effects of progestins on the circulating IGF-I system Maturitas 46 S1 2003 S39 S44
123. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast, cancer Lancet 350 9084 1997 1047 1059
124. C. Campagnoli, S. Ambroggio, N. Biglia, and P. Sismondi Conjugated estrogens and breast cancer risk Gynecol. Endocrinol. 13 S6 1999 S13 S19
125. M.H. Jeng, C.J. Parker, and V.C. Jordan Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation Cancer Res. 52 23 1992 6539 6546
126. L. Markiewicz, R.B. Hochberg, and E. Gurpide Intrinsic estrogenicity of some progestagenic drugs J. Steroid Biochem. Mol. Biol. 41 1 1992 53 58
127. T. Rabe, M.K. Bohlmann, S. Rehberger-Schneider, and S. Prifti Induction of estrogen receptor-alpha and -beta activities by synthetic progestins Gynecol. Endocrinol. 14 2 2000 118 126
128. J.H. Thijssen Oestrogens, progestins and breast proliferation Zentralbl. Gynakol. 119 1997 43 S47
129. J.R. Pasqualini, G. Chetrite, C. Blacker, M.C. Feinstein, L. Delalonde, M. Talbi, and C. Maloche Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients J. Clin. Endocrinol. Metab. 81 4 1996 1460 1464
130. J.R. Pasqualini Differential effects of progestins on breast tissue enzymes Maturitas 46 S1 2003 45 54
131. C.P. Spencer, I.F. Godsland, A.J. Cooper, D. Ross, M.I. Whitehead, and J.C. Stevenson Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women Metabolism 49 6 2000 742 747
132. I.F. Godsland, K. Gangar, C. Walton, M.P. Cust, M.I. Whitehead, V. Wynn, and J.C. Stevenson Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy Metabolism 42 7 1993 846 853
133. K.E. Elkind-Hirsch, L.D. Sherman, and R. Malinak Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure J. Clin. Endocrinol. Metab. 76 2 1993 472 475
134. C. Campagnoli, N. Biglia, M.G. Lanza, L. Lesca, C. Peris, and P. Sismondi Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report Maturitas 19 1 1994 25 31
135. A. Heald, P.L. Selby, A. White, and J.M. Gibson Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis Am. J. Obstet. Gynecol. 183 3 2000 593 600
136. A.G. Nugent, K.C. Leung, D. Sullivan, A.T. Reutens, and K.K. Ho Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women Clin. Endocrinol. (Oxford) 59 6 2003 690 698
137. M.F. McCarty Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity Med. Hypotheses 56 2 2001 213 216
138. V.T. Miller, R.A. Muesing, J.C. LaRosa, D.B. Stoy, E.A. Phillips, and R.J. Stillman Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I Obstet. Gynecol. 77 2 1991 235 240
139. K. Bakken, E. Alsaker, A.E. Eggen, and E. Lund Hormone replacement therapy and incidence of hormone-dependent cancers in the norwegian women and cancer study Int. J. Cancer 112 1 2004 130 134